Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Memgen, Inc.
Incyte Corporation
Eli Lilly and Company
Fate Therapeutics
Nektar Therapeutics
Nektar Therapeutics
Jules Bordet Institute
Incyte Corporation
Duke University
Infinity Pharmaceuticals, Inc.
Sheba Medical Center
MultiVir, Inc.
National Cancer Institute (NCI)